secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0001104659-25-102834
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa Q3 ARCALYST revenue $180.9M (+61% YoY); raises 2025 guidance to $670-675M
--------------------------------------------------------------------------------

- Net income $18.4M (vs loss $12.7M); cash $352.1M, no debt.
- ARCALYST net product revenue $180.9M, up 61% YoY; total revenue $180.9M.
- 2025 revenue guidance raised to $670-675M from prior $625-640M.
- KPL-387 granted Orphan Drug Designation; Phase 2/3 data H2 2026.
- Prescribers >3,825; average therapy duration ~32 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465925102834/0001104659-25-102834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465925102834/tm2529531d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-102834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer